PDCD1 and neoplasm: Nivolumab, a fully human mAb with a molecular weight of 146 kDa, targets PD-1 to block its interaction with PD-L1 and PD-L2 and subsequently avoiding PD-1 mediated inhibition of anti-tumor responses [93].